Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
Geburtshilfe und Frauenheilkunde · 01.03.2023 · 83 (03) · 299-309
DOI: 10.1055/a-2018-9184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.03.2023. Verfasst von Diana Lüftner und 23 weiteren Autor:innen. Beteiligte Einrichtung: Immanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody–drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody–drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany.
- Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
- Onkologie Aschaffenburg, Aschaffenburg, Germany.
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
- Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany.
Zitieren
APA
Lüftner, D., Lux, M. P., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Beierlein, M., Belleville, E., Untch, M., Thill, M., Ditsch, N., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., Wöckel, A., …, & Hartkopf, A. D. (2023). Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(03), 299-309. https://doi.org/10.1055/a-2018-9184
Vancouver
Lüftner D, Lux MP, Fehm TN, Welslau M, Müller V, Schütz F, et al. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde. 2023;83(03):299-309. doi:10.1055/a-2018-9184
BibTeX
@article{Lftner2023,
author = {Lüftner, Diana and Lux, Michael P and Fehm, Tanja N and Welslau, Manfred and Müller, Volkmar and Schütz, Florian and Fasching, Peter A and Janni, Wolfgang and Thomssen, Christoph and Witzel, Isabell and Beierlein, Milena and Belleville, Erik and Untch, Michael and Thill, Marc and Ditsch, Nina and Aktas, Bahriye and Banys-Paluchowski, Maggie and Kolberg-Liedtke, Cornelia and Wöckel, Achim and Kolberg, Hans-Christian and Harbeck, Nadia and Stickeler, Elmar and Tesch, Hans and Hartkopf, Andreas D},
title = {Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2023},
volume = {83},
number = {03},
pages = {299--309},
doi = {10.1055/a-2018-9184}
}
EUVIMED